文献速递治疗药物监测与药物基因组学特殊人群用药

基因型指导的小儿实体器官移植他克莫司贝叶斯给药证据系统综述

Evaluating the evidence for genotype-informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review.
PubMed 文献 · Br J Clin Pharmacol · 2024-08-15

该系统综述检索了2013年3月至2023年3月Medline、Embase和Cochrane数据库,纳入7项研究,探讨移植前基因分型联合药代动力学模型指导儿童实体器官移植后他克莫司给药。综述指出临床与遗传因素共同显著影响他克莫司清除率及初始剂量推荐,但现有模型存在局限,缺乏有效性证据,需前瞻性研究验证。

要点

  • 基因型与临床协变量整合的PK模型可用于个体化儿童移植早期他克莫司剂量。
  • 体表面积、移植器官和合并用药是影响他克莫司清除率的持续重要因素。
  • 现有模型尚缺前瞻性验证,有效性证据不足。

核心结论

  • 基因型与PK模型整合的个体化给药在儿童实体器官移植中有潜力,但需前瞻性研究验证其有效性。

研究设计与样本

  • 系统综述,检索Medline、Embase和Cochrane数据库2013年3月至2023年3月发表的文献,纳入7项研究,用Newcastle-Ottawa量表评估质量。

主要发现

  • 7项研究涵盖儿童肾、心、肝和肺移植,报告了使用基因型和模型指导给药。
  • 临床与遗传因素联合显著影响他克莫司清除率及初始剂量推荐。
  • 体表面积、移植器官和合并用药 consistently 重要,部分研究中移植后时间或血细胞比容也出现。
  • 识别出多个模型,但部分存在局限,且缺乏优化初始及后续剂量的有效性证据。

关键数值与推荐

  • 体表面积、移植器官和合并用药是影响他克莫司清除率的关键协变量。
  • 部分模型中移植后时间或血细胞比容为相关因素。

临床怎么用

  • 临床可考虑移植前基因分型联合PK模型辅助儿童实体器官移植早期他克莫司初始剂量决策。
  • 目前证据尚不足以常规推广,需结合临床监测并等待前瞻性验证。

局限性

  • 纳入研究数量有限(7项),部分模型存在局限。
  • 缺乏模型在优化初始和后续剂量方面的有效性证据。
  • 需前瞻性研究验证模型对达标时间和暴露不足或过度的改善效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tacrolimus, a calcineurin inhibitor, is a highly effective immunosuppressant used in solid organ transplantation (SOT). However, it is characterized by a narrow therapeutic range and high inter-patient variability in pharmacokinetics. Standard weight-based dosing followed by empiric dose titration is suboptimal in controlling drug concentrations, increasing risk of rejection or toxicity, particularly in the initial months post transplantation. This review explores the potential of combined pre-transplant genotyping and pharmacokinetic (PK) modelling to improve tacrolimus dosing in paediatric SOT recipients. A systematic search of Medline, Embase and Cochrane databases identified studies published between March 2013 and March 2023 that investigated genotype- and PK model-informed tacrolimus dosing in children post-SOT. The Newcastle-Ottawa Scale assessed study quality. Seven studies encompassing paediatric kidney, heart, liver and lung transplants reported using genotype and model-informed dosing. A combination of clinical and genetic factors significantly impacts tacrolimus clearance and thus initial dose recommendation. Body size, transplant organ and co-medications were consistently important, while either time post-transplant or haematocrit emerged in some studies. Several models were identified, however, with limitations evident in some and with absence of evidence for their effectiveness in optimizing initial and subsequent dosing. This review highlights the development of PK models in paediatric SOT that integrate genotype and clinical covariates to personalize early tacrolimus dosing. While promising, prospective studies are needed to validate and confirm their effectiveness in improving time to therapeutic concentrations and reducing under- or overexposure. This approach has the potential to optimize tacrolimus therapy in paediatric SOT, thereby improving outcomes.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Khatri D, Felmingham B, Moore C, et al. Evaluating the evidence for genotype-informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review. Br J Clin Pharmacol. 2024. PMID: 39147586. doi:10.1111/bcp.16203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。